
The Cambridge, U.K.–based surgical robot developer picked Colella as its interim CEO last year when Supratim Bose left the post. After about three months in the corner office on a temporary basis, Collela now takes over as a permanent fixture. He originally joined CMR Surgical as chief commercial officer in December 2023.
Within a week of Colella’s appointment as interim CEO, the FDA cleared the company’s Versius surgical robot platform. He’s since helped drive growth in installed base and helped bring Versius to more hospitals around the world, the company says.
Colella brings more than 30 years of senior healthcare leadership experience to the corner office at CMR Surgical. He held senior roles at Johnson & Johnson and Smith+Nephew before serving as CEO at Evercare Group.
He now leads the company as it brings Versius to the U.S. market. CMR Surgical designed Versius to enable surgeons to perform more minimal access surgery. Its minimally invasive approach assists surgeons in accessing the lungs, thymus and esophagus. The small-scale surgical robotic system features collaborative arms and bedside units for direct patient access. It also features offers of port placement to best suit the needs of each patient.
“It is a real honor, and responsibility to be leading CMR,” Colella said. “I have seen first-hand the dedication of our people who provide excellent service to our existing customers, and are passionate about bringing the benefits of robotic-assisted minimal access surgery to more patients globally. With FDA marketing authorization for Versius, and significant new products and instruments further strengthening the Versius offering, this is a very exciting time for CMR.”